Objectives-Strategies are needed for the identification of a poor response to treatment and determination of appropriate chemotherapy strategies for patients in the early stages of neoadjuvant chemotherapy for breast cancer. We hypothesize that power Doppler ultrasound imaging can provide useful information on predicting response to neoadjuvant chemotherapy.
N eoadjuvant chemotherapy is aimed at reducing the tumor size and stage to increase the chances of successful breastconserving surgery, and is used to treat occult micrometastatic breast cancer disease. 1 The clinical response rate of neoadjuvant chemotherapy is over 70%, and approximately 30% of responders exhibit a pathologic complete response (pCR). 2 Pathologic complete responses are most significantly associated with the likelihood of benefit, as measured by disease-free and overall survival together with the lymph node status at surgery. 3 Approximately 30% of patients are poor or nonresponders, showing no clinical or pathological benefit. patients who are likely to benefit from treatment. It will also identify individuals with low or no likelihood of benefit, thereby sparing them the toxicity of an inactive treatment and allowing earlier surgical intervention or alternative approaches.
A patient's response to neoadjuvant chemotherapy is currently assessed using the combination of clinical examination and conventional imaging techniques, such as mammography and breast ultrasound. In addition to traditional texture and shape analysis using computer graphics, blood flow can also be used to predict neoadjuvant chemotherapy response, as ultrasound imaging can demonstrate the microcirculation of a breast tumor and reveal the perfusion of the vessels. The growth and metastasis of tumors require that the tumor cells have access to blood vessels. Therefore, vascular perfusion in tumors is an important topic in cancer research and treatment. In addition, many studies have demonstrated the relationship between tumor angiogenesis and prognosis as determined by the microvessel density and the correlation between measures of tumor perfusion and the response to therapy. [5] [6] [7] The variation of vascular perfusion in a tumor may influence the effect of chemotherapy in breast cancer. By comparing the perfusion variance before and after each period of neoadjuvant chemotherapy, the transport capacity of the tumor vessel was characterized and used as a marker in the evaluation of the chemotherapeutic response in breast cancer.
The most popular techniques for the detection of tumor vessel perfusion include ultrasound (US), positron emission tomography, and magnetic resonance imaging. However, the cost and the use of radiopharmaceutical agents of magnetic resonance imaging and positron emission tomography limits the number of times a patient can be evaluated during the course of treatment. In comparison, breast US is a conventional imaging technique that is more accessible and less expensive, and it can be used without harm for repeat inspections of the same lesion. The advent of three-dimensional (3D) power Doppler US provides high-resolution Doppler signal reflection, allowing the observation of a tumor vascular mass. 8 This technique is not limited by the angle of the vessel, and it allows 3D imaging of the relevant vessels, as well as quantitative assessment of the vessel density and perfusion within a specified area. 9, 10 The highdefinition flow (HDF) US technique provides better axial resolution and fewer blooming artifacts than PD US, and it provides solid directional flow information and high-definition images. 11 A preliminary study also indicated that HDF may be preferable for assessing small vessels, such as microvascularization assessment in cases of malignant tumors, because it appears to be more sensitive for codifying Doppler signals than PD. 12 In this study, the 3D-HDF US was used to quantify blood flow index variability and identify differences associated with varying levels of chemotherapeutic response. Another challenge is how to classify patients with a good and poor response after treatment based on the changes in vascular flow indices. Choosing an appropriate classifier may help to increase the accuracy of prediction and classification. This issue presents a challenge in machine learning, because the variances between each cycle of chemotherapy are usually very small. After evaluating several methods including the Markov model 13 and neural networks 14 to compare the performances of prediction, support vector machines (SVMs) were found to be superior to others. They allow for good out-of-sample generalization, and despite the existence of minor bias in the training set, the results of this process are rather robust. 15 To make the 3D-HDF US and SVMs suitable for the investigation, and to have a good prediction and classification in this study, several strategies were combined to enhance the sensitivity and specificity of this method. A flow chart describing the study procedures is shown in Figure 1 . These procedures were used to guide the development of chemotherapeutic strategies for patients with pCR or partial response (PR) in the early stages of neoadjuvant chemotherapy.
Materials and Methods

Patient Characteristics
This retrospective study was approved by the institutional review board; informed consent was obtained from all patients before participation. From July 2007 to October 2010, we recruited 96 consecutive patients of a single surgeon (one of the authors of this paper). Considering that each chemotherapy drug plays a different role in angiogenesis, and that at least three regimens are administered according to the breast cancer treatment guidelines at our hospital-(1) 5-fluorouracil 1 epirubicin 1 cyclophosphamide (FEC), (2) After excluding patients without a continuous sequence of US image sets (absence of any of 6 cycles of US images) and those who received non-FEC regimens (taxane-based and trastuzumab-targeted therapy), 31 breast cancer patients were finally enrolled. Women with newly diagnosed, nonmetastatic, histologically proven, locally advanced breast cancer received 6 cycles of a neoadjuvant regimen every 3 weeks. Because of the size limitation of the ultrasonic transducer, the enrolled patients were limited to stage T2 (tumor size 2-5 cm) under the tumor, node, and metastasis system, according to the 6th American Joint Committee on Cancer. 16 The mean tumor size measured by 3D-HDF US before the neoadjuvant regimen in the patient cohort was 3.2 3 2.9 cm. After the neoadjuvant regimen, the mean tumor size measured in pathology was reduced to 1.5 cm.
Fine needle aspiration cytology was performed for all enrolled patients to define the axillary staging. Mastectomy specimens were formalin-fixed, paraffin-embedded, sectioned, and stained with hematoxylin-eosin. Sixteen patients were positive for axillary lymph node metastasis (51.6%). Three patients were positive for mixed carcinoma or mucinous adenocarcinoma (9.68%), and 28 patients had infiltrated ductal carcinoma (90.32%).
The expression of estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2) was evaluated in surgical and core needle biopsy specimens for immunohistochemistry with the Roche Ventana Benchmark XT auto-stainer. Estrogen receptor was evaluated with Clone SP1 antibody, PgR was evaluated with 1E2 antibody, and HER2 was evaluated with 4B5 antibody according to the protocol provided by the manufacturer (Ventana/Roche, Ventana Medical Systems, Tucson, AZ). Estrogen receptor and PR status was assessed by Allred scoring; scores greater than 3 were regarded as positive. Human epidermal growth factor receptor 2 staining was scored as 0, 11, 21, or 31. Tumors with a 31 score were classified as HER2-positive; all others were classified as negative. This classification yielded 21 ER-positive patients (67.74%); 28 PgR-positive patients (90.32%); and 13 HER2-positive patients (41.9%). No triple-negative patients were identified in the study population. Outcomes following primary chemotherapy, ER/PR/HER2 status, and tumor size are summarized in Table 1 . Figure 2 shows the complete course of neoadjuvant chemotherapy and the predefined time points for US image acquisition. Three time points were predefined as follows: (1) P0: before core needle biopsy; (2) P1: Each US image was obtained before injection of the chemotherapy drug. Nonharmonic and harmonic 3D-HDF PD US images were obtained using a GE Voluson 730 US system (GE Healthcare, Zipf, Austria), equipped with a relative stopping power index transducer for 3D volume scanning (relative stopping power, 6-12 MHz) and tissue harmonic imaging modalities. The following fixed pre-installed settings were used for all subjects: midfrequency, 0.9-kHz pulse repetition frequency, 0.6 gain, and "low 1" wall motion filter. All subjects were examined in a supine position with an arm extended overhead. No stand-off pad was used. The probe was held still, using enough jelly to ensure gentle contact with the skin and to avoid exerting undue pressure. The subjects were asked to hold their breath for approximately 20 s, if possible, while the scanner generated the 3D volume. All enrolled patients were scanned with 208 sweep angles, and all examinations were performed by a single physician with more than 20 years of breast US experience (one of the authors).
3D-HDF PD US
Chemotherapy Periods and Response Definition
Chemotherapeutic response was classified according to the guideline of the Response Evaluation Criteria in Solid Tumors (RECIST) working group. 17 The initial tumor size was investigated with 4D View, version 5.0 (GE Kretztechnik, Zipf, Austria), and the postneoadjuvant tumor size was determined by the pathologist. The initial tumor size was determined by selecting Table 1 lists the initial tumor size as determined by echo, the post-neoadjuvant pathological tumor size, the percent decrease in tumor size, and the chemotherapy response.
Volume of Interest Extraction
A physician with more than 10 years of experience in breast US image interpretation (one of the authors) manually determined the contours of the tumor for each patient. Six preliminary two-dimensional (2D) contours were manually sketched on image slices on six axes at 08, 308, 608, 908, 1208, and 1508 of the volume of interest (VOI), and these slides were used as references for 3D contour building. Three-dimensional contour of VOI was automatically estimated with a customized system described elsewhere. 18 Because of the blurred borders on the US images, an additional volume, known as the dilated volume, in which the tumor volume is 3 mm 3 greater than the original volume, was added to minimize deviations after the contours were sketched by physicians. Relative to the exact tumor volume, the inner volume was derived from the sketched tumor contours. Two areas were processed separately in feature extraction. Figure 3 shows the sketched tumor margin on harmonic 3D-HDF images and an established 3D contour. Figure 3A demonstrates how the margin was sketched on the 2D slice B-mode US image at 308 (#115 of image set), 608 (#62 of image set), and 908 (#137 of image set), and then the 3D contours were established. Figure   3B shows the full image with 3D contours and the flow direction of the tumor vasculature.
Estimation of Vascularization and Flow Index
Three most meaningful vascularity indices of flowvascularization index (VI), flow index (FI), and vascularization-flow index (VFI)-within 3D-HDF PD imaging 19 were extracted from the VOI. The VI represents vessel density, FI represents the average flow intensity, and VFI represents vascularization and flow intensity (similar to perfusion). 20 For more precise observation of the blurred tumor borders on US images, two vascular quantization feature sets were also predefined and separately processed: dVI/dFI/dVFI represents the flow indices of the dilated volume; and iVI/ iFI/iVFI represents the flow indices of the tumor volumes. These indices were repeatedly measured to avoid intra-observer error and improve reproducibility.
Prediction of Chemotherapy Response in SVMs
Most vascular features extracted in this study resulted in nonlinear data that were difficult to classify directly. The SVMs are supervised learning models for solving nonlinear, nonparametric classification problems, particularly suitable for binary classification. 21 In this study, Csupport vector classification 22 was chosen for the formulation using an SVM. The radial basis function kernel was chosen for the kernel function after the performance estimate. The implementation used was the open-source machine learning library LibSVM. 23 Unlike traditional statistical methods, resolution of the classification problem in the SVM is dependent on optimal mapping of the high-dimensional data space by using a nonlinear mapping algorithm and finding a hyperplane to divide these eigenvalues. 24 Figure 4 illustrates the method of data clustering and how to identifying a hyperplane in SVM. The 3D vascular indices VI, FI, and VFI from the inner or outer volume were extracted and scaled to floating points numbered from 21 to 1 by normalization, according to the total distribution, and converted into a vector, designated as the eigenvalue. These features were converted into vectors and entered into the SVM classifier to evaluate the response to neoadjuvant chemotherapy. All eigenvalues were mapped in the multidimensional data space by a mapping function f x ð Þ, and the hyperplane was the basis of classification. These affiliated eigenvalues were used to construct a matrix that was entered into the C-support vector classification model to classify responding patients. After the selection of appropriate cost function C and kernel parameter g. Predictive performance was evaluated by the area under the ROC curve (AUC) using the five-fold cross-validation procedure. 25 
Descriptive Statistics of Vascular Indices
The mean and standard deviation of the vascular indices VI/FI/VFI at each chemotherapy cycle in pCR/PR and poor responders were calculated. A student t-test was used to obtained the mean of the vascular indices in 95% confidence interval within 2 standard deviations. All analyses were performed with the statistical software package SPSS, version 22 (IBM Corp, Armonk, NY). Figure 5 summarizes the vascular and perfusion features by tumor receptor status (ER/PgR and HER2) and tumor grades. The means and the distributions of VI/ FI/VFI for all patients are drawn in the box-whisker plot. Over 87% of the pCR patients were distinguished after the second chemotherapy administration (P2) (AUC 5 0.7, accuracy 5 83.87%), and over 80% of the pCR patients were distinguished before the first chemotherapy administration (P0) (AUC 5 0.76, accuracy 5 87.9%). Figure 6 shows the pCR and the responder prediction performance of evaluations at P0, P1, and P2. In Figures 6A and 6B , the pCR prediction is shown at first. Because the lower AUC reveals its lower degree of discrimination, the pCR prediction after the first chemotherapy administration was discarded (AUC 5 0.3). The pCR prediction was the most accurate at P2.
Results
In total, 87.1% of the responders were distinguished after the second chemotherapy administration (P2) (AUC 5 0.88), and 80.65% of the responders were distinguished before the first chemotherapy administration (P0) (AUC 5 0.75). The pCR and PR patients were initially combined and defined as the responder group. In Figures 6D to 6F , the responder prediction result is shown. The AUC for the responder prediction after first chemotherapy administration (P1) was greater than the pCR prediction, although it still had a lower degree of discrimination; therefore, the responder prediction at P1 was also discarded (AUC 5 0.52). The responder prediction was also the most accurate at P2.
After analysis of the vascular indices after each cycle of chemotherapy, we found that there was significant variation. The effect of the chemotherapy drug may account for this result, because the primary effect of most chemotherapy drugs is to shrink the tumor and disrupt the blood supply. Chemotherapy reduces the vasculature of the tumor and affects the vascular flow indices collected through US imaging. Assuming these variances are meaningful, the concept of slope was Figure 4 . Schematic representation of the data clustering and hyperplane identification in SVM. All eigenvalues were mapped in the multidimensional data space by the mapping function f(x); finding the hyperplane was the basis of classification.
applied and three formulas were defined to help improve the classification ([P 0 2P 1 ]/P 0 , [P 0 2P 2 ]/P 0 , and [P 1 2 P 2 ]/P 1 ). Figure 7 shows the performance of each formula. The best formula for predicting pCR was [P 0 2P 2 ]/P 0 , with an accuracy of 87.1% (AUC 5 0.82). It is even better than the predicting of pCR in P0 or P2.
This was also the pretty good performance formula for predicting responders, with an accuracy of 80.65% (AUC 5 0.85). Figure 8 shows the mean and standard deviation of the vascular indices VI/FI/VFI at each chemotherapy cycle in pCR/PR and poor responders. The curves of VI and VFI from P0 to P3 in all types of patients had similar trends. In the responder category (pCR/PR patients), the peak values of VI and VFI were in P1. The higher SD shows that the variation of VI and VFI of the PR group in P1 were larger than that of the pCR group (iVI 5 0.015 in PR; 0.08 in pCR; iVFI 5 1.09 in PR; 0.46 in pCR, P < .05 in all groups). The peak VI (mean iVI 5 0.014) and VFI (mean iVFI 5 0.95) values of the PR group in P1 were also higher than that of the pCR (mean iVI 5 0.007, mean iVFI 5 0.4) group. In the poor responder category (PD/SD patients), the VI (mean iVI 5 0.017) and VFI (mean iVFI 5 1.06) values peaked at P0 and then declined, with only slight variation from P1 to P3 (mean iVI 5 0.0135 to 0.0138, mean iVFI 5 0.087 to 0.091, P < .05).
The trend of the FI curve in the complete response group during each chemotherapy cycle differed from the others. In the FI curve in the pCR patients, the peak occurred at P0 (mean iFI 5 55.78), followed by a significant decline from P1 (mean iFI 5 55.26) to P2 (mean iFI 5 41.72). However, the SD of FI at P2 and P3 was larger than that of the others (SD of iFI 5 18.11 at P2, 26.62 in P3). In the PR patients, the trend of the FI curve exhibited a significant decline from P1 (mean iFI 5 62.59) to P2 (mean iFI 5 59.26); from P0 to P3, the variation of FI was slight and stable (mean iFI 5 62.48-60.32). In PR and SD patients, the trend of the FI curve showed stable and slight growth from P0 (mean iFI 5 62.01) to P2 (mean iFI 5 62.01-66.05), and it declined slightly from P2 to P3 (mean iFI 5 66.05-65.48). In the poor responder category, the peak of the FI curve occurred at P2.
Discussion
Combining the pathology data (histology, grade, tumor biomarker expression) with sonography or mammography features, or adding additional imaging features to improve the predictive accuracy is a well-known approach and has demonstrated a good prediction performance. 26, 27 However, the acquisition of pathology data and assessment of additional image features requires further analysis, as this can be labor-intensive work. In this study, the analysis was simply based on the variation of fundamental vascular flow indices, and our preliminary results show that these variations provide sufficient information to directly improve the observation of the chemotherapy response. Even the acquisition of a sonograph is dependent on highly experienced experts and is associated with several unavoidable biases. Nonetheless, the accuracy of quantitative assessment by the 3D-HDF US technique can be well substantiated in appropriate settings. Figure 6 shows the poor performance of the prediction of pCR/PR patients and poor responders at P1 after our preliminary analysis; this was not a result of user error when acquiring the US image (all US images were acquired by the same surgeon). This suggests that the low performance of prediction at P1 is caused by the lack of the consistency of the vascular flow indices in patients. In our experimental design, the tumor volume was first divided into the inner and outer volumes beforehand with a 3-mm buffer to reduce the effect of bias when selecting the tumor borderline (see the "Materials and Methods" section). Figure 8 shows that the large variations of VI and VFI of the inner volume (iVI/iVFI) and the outer volume (dVI/dVFI) were similar, thus ruling out user error. It also shows that to predict the response of patients undergoing neoadjuvant chemotherapy at P1 is inappropriate. Figure 8 also shows that the trend of FI in the vascular flow at each time point differed in the poor responder group compared with the pCR and PR groups. This is valuable information to help distinguish between good and poor responders to chemotherapy, and can be easily observed from the variation in FI. For example, in the pCR and PR patients, the trend in FI decreases from P0 to P2; the range of FI decrease in PR patients is less than pCR patients. In contrast, the trend FI increases from P0 to P2 in the poor responder, such as PD/SD patients.
Expression of the breast cancer biomarkers ER, PR, and HER2 is used widely to evaluate chemotherapy adjustment strategies. However, the expression status only predicts the chemotherapeutic response with 40% accuracy. 28 Similar predictive accuracy was obtained by applying the ER/PR/HER2 expression status as the SVM input in our test. The AUC was low; therefore, the prediction performance was poor (AUC in the prediction of pCR patients was 0.45 and 0.3188 in the prediction of responder patients; the accuracy of all predictions was >70%). This indicates that the predicting chemotherapeutic response based on ER/PR/HER2 only is unreliable, and combining the pathology data or US image data may be great in improving the prediction performance.
Finally, the small sample size is the primary disadvantage of this study. To avoid overestimating the prediction performance, AUC evaluation combining the five-fold examination was applied to evaluate the performance and eliminate the influence of sample size. 29 Several previous studies also indicated that even in the presence of bias in the training set, SVMs provide the distinct advantage of adaptability and generate robust results. [30] [31] [32] The predictive model can be improved by adjusting for additional US data.
In conclusion, the goal of this study was to develop a method to reduce the use of inappropriate therapies in poor responders, and to guide the selection of appropriate alternatives. We conclude that approximately more than 83% of pCR patients (AUC 0.7) and over 80% of PR patients (AUC > 0.75) can be predicted before the initiation of chemotherapy. More than 87% of pCR patients (AUC 0.75-0.82) and PR patients (AUC 0.88) can be distinguished before the third cycle of chemotherapy, approximately. Patients will benefit from improvements in the accuracy of predictions of the chemotherapy response.
The variations of lesion vascularity found in US images can aid in the evaluation of the chemotherapy response in breast cancer; however, several limitations were present. First is the selection bias; all patients were enrolled by one surgeon, and the chemotherapy therapy regimen was limited to an anthracycline-based regimen. Second is the smaller sample size; a sample of 31 patients cannot comprehensively include all combinations of ER/PR/HER2 expression status in breast cancer patients. In particular, our sample included fewer HER2-positive patients. The results of this study need to be viewed with caution, particularly in the case of the HER2-positive patients. Nevertheless, as a pilot study, this work provides a preliminary suggestion that using the blood flow of a tumor may be a feasible predictor of neoadjuvant chemotherapeutic efficacy. Extension of the sample of patients to achieve balance and the inclusion of other chemotherapy regimens are needed.
